Based on current and previous studies, the Cur + Pip has shown promising potential as an adjunct therapy for improving liver enzyme levels and inflammatory status, particularly in overweight adults with metabolic dysfunctions such as NAFLD and metabolic syndrome. The gene discussed is PIP; the disease is metabolic syndrome.